Cagrilintide: The GLP Partner
Next-Generation Peptide for Metabolic Health & Weight Management
NZ$140.00
Cagrilintide: The GLP Partner (5MG)
Cagrilintide is a next-generation, long-acting peptide being developed for obesity and cardiometabolic health, designed to amplify satiety, curb appetite, and support sustained weight loss. By activating amylin and calcitonin receptors in key appetite-regulating areas of the brain, it slows gastric emptying, prolongs fullness after meals, and helps reduce overall caloric intake without relying on stimulants.
Clinical data suggest meaningful weight reductions on its own, with even greater effects when paired with GLP-1 agonists like Tirzepatide or Retatrutide, positioning Cagrilintide and CagriGLP1-style combinations as a promising new frontier in metabolic and weight-management therapeutics.